Jun 2026 (Q2 FY26) — Aug 6, 2026
FS KKR Capital Corp. Q2 FY26 — Strategic Actions Underway, NAV Decline
Read the full callFS KKR Capital earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -34.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
1Y: $15.12 on 14 Oct 2025 → $10.73. High $16.13 (26 Nov 2025), low $9.91 (27 Mar 2026).
Overview
Call summaries
FS KKR Capital Corp. Q2 FY26 — Strategic Actions Underway, NAV Decline
Read the full callEvery analysed call
Financials
Net profit, year on year: +84% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Net profit | 160 | 147 | 120 | -209 | 214 | -114 | -441 | -34 |
| EPS ($ per share) | 0.57 | 0.52 | 0.43 | -0.75 | 0.76 | -0.41 | -1.57 | -0.13 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | — | 0 | 0 | 0 | 0 | 0 |
| Reserves | — | — | -1,928 | -2,598 | -2,588 | -2,662 | -3,350 |
| Total liabilities | — | — | 9,498 | 9,112 | 8,620 | 7,597 | 7,880 |
| Total assets | — | — | 17,228 | 16,124 | 15,469 | 14,219 | 13,729 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | 675 | -639 | 1,107 | 1,384 | 1,901 | 592 |
| Cash from financing | -590 | 825 | -1,233 | -1,404 | -1,836 | -679 |
| Net cash flow | 85 | 186 | -126 | -20 | 65 | -88 |
7 filings between Nov 7, 2025 and Aug 31, 2026.
Purchases
$411.5K
7 purchases by 4 insiders
Sales
None
No insider sold shares.
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Pietrzak Daniel | $207.8K | — | Feb 27, 2026 |
| Forman Michael C. | $155.0K | — | Nov 11, 2025 |
| KROPP JAMES H | $31.9K | — | Aug 11, 2026 |
| Hopkins Jerel A | $16.9K | — | Aug 31, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Hopkins Jerel A Director | Purchase | 800 | $9.9K |
| Aug 11, 2026 | KROPP JAMES H Director | Purchase | 1,100 | $13.3K |
| Feb 27, 2026 | KROPP JAMES H Director | Purchase | 1,666 | $18.6K |
| Feb 27, 2026 | Pietrzak Daniel President and CIO | Purchase | 5,000 | $56.3K |
| Dec 5, 2025 | Hopkins Jerel A Director | Purchase | 450 | $7.0K |
| Nov 11, 2025 | Forman Michael C. Chief Executive Officer | Purchase | 10,000 | $155.0K |
| Nov 7, 2025 | Pietrzak Daniel President and CIO | Purchase | 10,000 | $151.5K |
| Sep 3, 2025 | Hopkins Jerel A Director | Purchase | 330 | $6.0K |
| Aug 15, 2025 | Adams Barbara Director | Purchase | 3,750 | $65.7K |
| May 29, 2025 | Hopkins Jerel A Director | Purchase | 700 | $14.9K |
| Jan 1, 2025 | Forman Michael C. Chief Executive Officer | Sale | 10,088 | $0 |
| Dec 6, 2024 | Hopkins Jerel A Director | Purchase | 500 | $10.7K |
| Dec 5, 2024 | Pietrzak Daniel Co-President and CIO | Purchase | 5,000 | $106.5K |
| Dec 4, 2024 | Sandler Elizabeth Director | Purchase | 1,000 | $21.2K |
| Dec 3, 2024 | Gerson Brian Co-President | Purchase | 5,000 | $110.4K |
| Nov 25, 2024 | IMASOGIE OSAGIE O Director | Sale | 40,885 | $900.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow FS KKR Capital Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading